KOICA donates Celltrion's Herzuma to Ukraine

Celltrion Healthcare Co. said on Monday that Herzuma (ingredient name: Trastuzumab) was dispatched to patients in Ukraine by the Korea International Cooperation Agency (KOICA).

The latest donation was led by KOICA at the Ukrainian government's request. KOICA purchased 5 billion won ($3.9 million) worth of Herzuma from Celltrion Healthcare and donated it to Ukraine.

It is understood that the Ukrainian government selected Herzuma after considering the efficacy and safety of treatment, and the trust it has gained with European doctors, given that the supply of treatments for breast and stomach cancers was disrupted by the war.

Trastuzumab is one of the best-known anti-cancer drugs and has been widely used in Europe for years to treat HER2-positive breast cancer and gastric cancer.

"As we are currently running the Remsima SC donation program in Turkey and Pakistan, we will continue to fulfill our social responsibility to promote global medical welfare," said a Celltrion Healthcare official.

Write to Jung-Eun Kim at likesmile@hankyung.com